Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients

Gynecological Endocrinology

Volumn 24, Issue 4, 2008, Pages 188-193

  Martínez, Francisca ^a   Clua, Elisabet ^a   Parera, Nuria ^a   Rodríguez, Ignacio ^a   Boada, Monserrat ^a   Coroleu, Buenaventura ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Agonist; Antagonist; Human menopausal gonadotropins; Long protocol; Oocyte donors; Ovarian stimulation; Pregnancy rates; Recipients; Recombinant follicle stimulating hormone

Indexed keywords

CHORIONIC GONADOTROPIN; ETHINYLESTRADIOL PLUS ETONOGESTREL; GANIRELIX; HCG LEPORI; HMG LEPORI; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PUREGON PEN; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBRYO TRANSFER; FEMALE; HUMAN; OOCYTE; PREGNANCY RATE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALGORITHMS; EMBRYO TRANSFER; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LEUPROLIDE; MENOTROPINS; OOCYTES; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; TISSUE DONORS; TRANSPLANTATION;

EID: 41649106666     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590801893331     Document Type: Article

References (14)

1. Sauer MV. Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy. Reprod Biomed Online 2006;12:153-162.
2. Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod 2006;21:2121-2125.
3. Lindheim SR, Morales J. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003;18:2048-2051.
4. Ricciarelli E, Sanchez M, Martínez M, Andrés L, Cuadros J, Hernandez E. Impact of the gonadotropin-releasing hormone antagonist in oocyte donation cycles. Fertil Steril 2003;79:1461-1463.
5. Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vandezwalmen P, Schoysman R, Makedos G. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 2005;20:1516-1520.
6. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH after cotreatment with GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:709-716.
7. Kolibianakis EM, Collins J, Tarlatzis B, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of GnRH-analogue used? A systematic review and meta-analysis. Hum Reprod 2006;12:651-671.
8. Al-Inany H, AbouSetta A, Mansour R, Serour G, Aboulghar M. GnRH agonist vs. antagonist in assisted reproduction: a Cochrane review. Reprod Biomed Online 2007;14:640-649.
9. Plachot M, Mandelbaum J, Junca A. Qualité de l'oocyte et de l'embryon et résultat de la FIV. Contracept Fertil Sex 1990;18:636-638.
10. Weiss N. Gonadotrophin products: empowering patients to chose the product that meets their needs. Reprod Biomed Online 2007;1:31-37.
11. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003;80:1086-1093.
12. Platteau P, Laurenti E, Albano C. An open, randomized single-centre study to compare the efficacy and convenience of follitropin β administered by a pen device with follitropin a administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2003;18:1200-1204.
13. Andersen AN, Devroey P, Arce JC for the MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006;21:3217-3227.
14. Bodri D, Vernaeve V, Guillén JJ, Vidal R, Figueras F, Coll O. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod 2006;21:2246-2251.